The combined effect of green tea and α-glucosyl hesperidin in preventing obesity: a randomized placebo-controlled clinical trial.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
24 09 2021
Historique:
received: 16 06 2021
accepted: 13 09 2021
entrez: 25 9 2021
pubmed: 26 9 2021
medline: 31 12 2021
Statut: epublish

Résumé

Green tea, a widely consumed beverage in Asia, contains green tea catechins effective against obesity, especially epigallocatechin-3-O-gallate (EGCG), but must be consumed in an impractically huge amount daily to elicit its biological effect. Meanwhile, citrus polyphenols have various physiological effects that could enhance EGCG functionality. Here we investigated the antiobesity effect of a combination of EGCG and α-glucosyl hesperidin, a citrus polyphenol, at doses that have not been previously reported to exert antiobesity effects by themselves in any clinical trial. In a randomized, placebo-controlled, double-blinded, and parallel-group-designed clinical trial, 60 healthy Japanese males and females aged 30-75 years consumed green tea combined with α-glucosyl hesperidin (GT-gH), which contained 178 mg α-glucosyl hesperidin and 146 mg EGCG, for 12 weeks. Physical, hematological, blood biochemical, and urine examinations showed that GT-gH is safe to use. At week 12, GT-gH prevented weight gain and reduced body mass index (BMI) compared with the placebo. Especially in those aged < 50 years, triglyceride and body fat percentage decreased at week 6, visceral fat level and body fat percentage decreased at week 12; body weight, BMI, and blood LDL/HDL ratio also decreased. In conclusion, taking GT-gH prevents weight gain, and the antiobesity effect of GT-gH was more pronounced in people aged < 50 years.

Identifiants

pubmed: 34561541
doi: 10.1038/s41598-021-98612-6
pii: 10.1038/s41598-021-98612-6
pmc: PMC8463579
doi:

Substances chimiques

Glucosides 0
Placebos 0
Tea 0
glucosyl hesperidin 432C95B6YE
Catechin 8R1V1STN48
epigallocatechin gallate BQM438CTEL
Hesperidin E750O06Y6O

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19067

Informations de copyright

© 2021. The Author(s).

Références

Sci Rep. 2017 Sep 11;7(1):11190
pubmed: 28894283
Front Pharmacol. 2018 Nov 22;9:1366
pubmed: 30524290
Nat Struct Mol Biol. 2004 Apr;11(4):380-1
pubmed: 15024383
Nutrients. 2020 May 28;12(6):
pubmed: 32481594
Biomed Pharmacother. 2017 Oct;94:362-373
pubmed: 28772214
Can Fam Physician. 2008 Nov;54(11):1529-33
pubmed: 19005120
Integr Med Res. 2014 Mar;3(1):16-24
pubmed: 28664074
J Immunol. 2017 Nov 1;199(9):3261-3269
pubmed: 28954885
Adv Exp Med Biol. 2002;505:113-22
pubmed: 12083455
Eur J Nutr. 2021 Apr;60(3):1277-1288
pubmed: 32661681
Obesity (Silver Spring). 2020 Jun;28(6):1008-1009
pubmed: 32227671
Mol Nutr Food Res. 2011 Jun;55(6):844-54
pubmed: 21538850
Antiinflamm Antiallergy Agents Med Chem. 2016;15(2):74-90
pubmed: 27634207
BMC Complement Altern Med. 2018 Nov 6;18(1):294
pubmed: 30400924
Sci Rep. 2016 Jan 28;6:19710
pubmed: 26818408
J Complement Integr Med. 2019 Jan 25;16(3):
pubmed: 30681971
Eur J Nutr. 2016 Feb;55(1):341-8
pubmed: 25669932
Complement Med Res. 2021;28(3):226-233
pubmed: 33302270
Curr Med Chem. 2018;25(37):4929-4945
pubmed: 28721824
EFSA J. 2018 Apr 18;16(4):e05239
pubmed: 32625874
Biomed Pharmacother. 2017 May;89:949-956
pubmed: 28292023
Ann N Y Acad Sci. 2002 Nov;973:435-7
pubmed: 12485906
J Clin Invest. 2013 Feb;123(2):787-99
pubmed: 23348740
Int J Cancer. 2010 Oct 15;127(8):1913-22
pubmed: 20104526
Sci Rep. 2016 Aug 11;6:29540
pubmed: 27511742
Biol Pharm Bull. 2002 Dec;25(12):1513-8
pubmed: 12499631
Sci Rep. 2015 Mar 31;5:9474
pubmed: 25824377
Nutr J. 2016 Jan 19;15:6
pubmed: 26786000
J Nutr Sci Vitaminol (Tokyo). 2016;62(4):249-256
pubmed: 27725410
Molecules. 2017 Aug 12;22(8):
pubmed: 28805687
Br J Nutr. 2011 Dec;106(12):1880-9
pubmed: 21736785
Int J Mol Med. 2016 Feb;37(2):398-406
pubmed: 26648562
Br J Nutr. 2014 Apr 14;111(7):1263-71
pubmed: 24299662
Front Pharmacol. 2020 Mar 27;11:364
pubmed: 32292344

Auteurs

Ren Yoshitomi (R)

Division of Applied Biological Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.

Mao Yamamoto (M)

Division of Applied Biological Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.

Motofumi Kumazoe (M)

Division of Applied Biological Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.

Yoshinori Fujimura (Y)

Division of Applied Biological Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.

Madoka Yonekura (M)

Agriculture and Biotechnology Business Division, Toyota Motor Corporation, Aichi, Japan.

Yasuyo Shimamoto (Y)

Agriculture and Biotechnology Business Division, Toyota Motor Corporation, Aichi, Japan.

Akari Nakasone (A)

Agriculture and Biotechnology Business Division, Toyota Motor Corporation, Aichi, Japan.

Satoshi Kondo (S)

Agriculture and Biotechnology Business Division, Toyota Motor Corporation, Aichi, Japan.

Hiroki Hattori (H)

Department of Medical Management and Informatics, Hokkaido Information University, Hokkaido, Japan.

Akane Haseda (A)

Department of Medical Management and Informatics, Hokkaido Information University, Hokkaido, Japan.

Jun Nishihira (J)

Department of Medical Management and Informatics, Hokkaido Information University, Hokkaido, Japan.

Hirofumi Tachibana (H)

Division of Applied Biological Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan. tatibana@agr.kyushu-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH